|
KMID : 1161920220190010014
|
|
Journal of Medicine and Life Science
2022 Volume.19 No. 1 p.14 ~ p.19
|
|
|
Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease
|
|
Yang Ji-Eun
Park Ji-Eun
Jo Jae-Min
Kim Young-Ree
Chang Jee-Won
Han Sang-Hoon
Han Chi-Wha
|
|
|
Abstract
|
|
|
|
We investigated the safety and efficacy of pemetrexed monotherapy in patients with lung adenocarcinoma and various renal conditions, including chronic kidney disease. We also analyzed whether baseline renal function affected progression-free survival (PFS). We retrospectively analyzed 71 patients who received maintenance-and second-line pemetrexed monotherapy. Patients were divided into two groups according to estimated glomerular filtration rate (eGFR): fair eGFR (>60 mL/min/1.73 m2) and lower eGFR (59 mL/min/1.73 m2 or less). The safety and efficacy were evaluated for each group. Median ages were 73.2 years in the lower eGFR group (n=28) and 64.5 years in the fair eGFR group (n=43). Patients with a lower eGFR achieved a median PFS of 4.7 months, while the median PFS for patients with a fair eGFR was 2.7 months. The difference between the two groups was not statistically significant (p=0.075). Both groups showed treatment-related low-grade hematological and non-hematological adverse events. Pemetrexed monotherapy is safe and effective in patients with lung adenocarcinoma with a lower eGFR.
|
|
|
KEYWORD
|
|
|
Pemetrexed, Adenocarcinoma of lung, The elderly, Chronic renal insufficiency
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|